Mobocertinib
This tyrosine kinase inhibitor is specifically designed to target a particular mutation in the EGFR gene—exon 20 insertions—that occurs in a subset of non-small cell lung cancer patients who do not respond well to standard EGFR inhibitors. It provides a targeted treatment option for this previously difficult-to-treat lung cancer subgroup.
Peso Molecular
585,7000 g/mol
LogP
4,40
TPSA
114,00 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …
Estrutura 2D
Cite this structure
Embed this structure
SMILES
C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C
InChI
InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36)
Molecular Formula
C32H39N7O4
HBD / HBA
2 / 9
Ligações Rotacionáveis
13
Átomos Pesados
43
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This tyrosine kinase inhibitor is specifically designed to target a particular mutation in the EGFR gene—exon 20 insertions—that occurs in a subset of non-small cell lung cancer patients who do not respond well to standard EGFR inhibitors. It provides a targeted treatment option for this previously difficult-to-treat lung cancer subgroup.
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.
Yes, Mobocertinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650319. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 118607832. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="mobocertinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/mobocertinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/mobocertinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/mobocertinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="mobocertinib"></drugfyi-drug>